US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Celyad Oncology SA

0.5000

0.0000

Volume:- -

Turnover:- -

Market Cap:20.71M

PE:-3.44

High:0.5000

Open:0.5000

Low:0.5000

Close:0.5000

Loading ...

Overview Company News Filings

Company Profile

Company Name:

Celyad Oncology SA

Exchange:

EXPERT

Establishment Date:

2004

Employees:

18

Office Location:

Axis Business Park,Rue André Dumont 9,Mont-Saint-Guibert,Walloon Brabant,Belgium

Website:

- -

Zip Code:

1435

Phone:

Fax:

32 1 039 41 41

Introduction:

Celyad Oncology SA, a clinical-stage biopharmaceutical company, focuses on the discovery and development of chimeric antigen receptor T (CAR-T) cell therapies for the treatment of cancer. Its lead product candidates include CYAD-101, an allogeneic CAR-T candidate that is in Phase 1b clinical trial for the treatment of metastatic colorectal cancer; CYAD-211, a short hairpin RNA (shRNA)-based allogeneic CAR-T candidate, which is in Phase 1 clinical trial to treat relapsed / refractory multiple myeloma; and CYAD-02, an autologous CAR-T candidate that is in Phase 1 clinical trial for the treatment of relapsed or refractory acute myeloid leukemia and myelodysplastic syndromes. It has licensing agreement with Novartis International AG regarding the United States patents related to allogeneic CAR-T cells; and research and development collaboration, and license agreements with Horizon Discovery Group plc for the use of its shRNA reagents to reduce expression of one or more defined targets. The company was formerly known as Celyad SA and changed its name to Celyad Oncology SA in June 2020. Celyad Oncology SA was founded in 2004 and is headquartered in Mont-Saint-Guibert, Belgium.

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/CLYYF/company"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"CLYYF","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"CLYYF\",,,,,undefined,":{"symbol":"CLYYF","market":"US","secType":"STK","nameCN":"Celyad Oncology SA","latestPrice":0.5,"timestamp":1751562000000,"preClose":0.5,"halted":0,"volume":0,"delay":15,"floatShares":14140089,"shares":41428572,"eps":-0.145542,"marketStatus":"Closed Independence Day","change":0,"latestTime":"07-03 13:00:00 EDT Delay","open":0.5,"high":0.5,"low":0.5,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"otc":true,"ttmEps":-0.145542,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1751875200000},"marketStatusCode":7,"adr":0,"adrRate":0,"exchange":"EXPERT","adjPreClose":0.5,"volumeRatio":3.678618498167212},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"CLYYF\",,,,,undefined,":{"symbol":"CLYYF","floatShares":14140089,"roa":"-27.99%","roe":"-170.92%","lyrEps":-0.145542,"volumeRatio":3.678618498167212,"shares":41428572,"dividePrice":0,"high":0.5,"amplitude":0,"preClose":0.5,"low":0.5,"week52Low":0.245,"pbRate":"34.42","psRate":"94.57","week52High":0.68,"institutionHeld":0,"latestPrice":0.5,"eps":-0.145542,"divideRate":0,"volume":0,"delay":15,"ttmEps":-0.145542,"open":0.5,"prevYearClose":0.245,"prevWeekClose":0.5,"prevMonthClose":0.5,"prevQuarterClose":0.5,"fiveDayClose":0.5,"twentyDayClose":0.5,"sixtyDayClose":0.65},"@#url:\"stock.company.info\",,undefined,":{"stockCompanyProfile":{"companyId":34816993,"yearFounded":2004,"employeeNum":18,"address":"Axis Business Park,Rue André Dumont 9,Mont-Saint-Guibert,Walloon Brabant,Belgium","zipCode":"1435","officePhone":"32 1 039 41 00","officeFax":"32 1 039 41 41"},"stockCompanyDetail":{"stockEarnings":[{"period":"1week","weight":0},{"period":"1month","weight":0},{"period":"3month","weight":0},{"period":"6month","weight":-0.5586},{"period":"1year","weight":-0.6125},{"period":"ytd","weight":-0.5586}],"description":"Celyad Oncology SA, a clinical-stage biopharmaceutical company, focuses on the discovery and development of chimeric antigen receptor T (CAR-T) cell therapies for the treatment of cancer. Its lead product candidates include CYAD-101, an allogeneic CAR-T candidate that is in Phase 1b clinical trial for the treatment of metastatic colorectal cancer; CYAD-211, a short hairpin RNA (shRNA)-based allogeneic CAR-T candidate, which is in Phase 1 clinical trial to treat relapsed / refractory multiple myeloma; and CYAD-02, an autologous CAR-T candidate that is in Phase 1 clinical trial for the treatment of relapsed or refractory acute myeloid leukemia and myelodysplastic syndromes. It has licensing agreement with Novartis International AG regarding the United States patents related to allogeneic CAR-T cells; and research and development collaboration, and license agreements with Horizon Discovery Group plc for the use of its shRNA reagents to reduce expression of one or more defined targets. The company was formerly known as Celyad SA and changed its name to Celyad Oncology SA in June 2020. Celyad Oncology SA was founded in 2004 and is headquartered in Mont-Saint-Guibert, Belgium.","exchange":"EXPERT","name":"Celyad Oncology SA","nameEN":"Celyad Oncology SA"}},"@#url:\"https://hq.skytigris.cn/fundamental/company/manager/list\",params:#symbol:\"CLYYF\",market:\"US\",,,undefined,":null,"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/CLYYF\",params:#limit:5,,,undefined,":[{"date":"2022-11-10","symbol":"CLYYF","type":"earning","reportTimeType":"","market":"US","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1668070800000,"name":null,"time":"","dateTimestamp":1668056400000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"CLYYF\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"CLYYF\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0,"buy":0,"hold":1,"sell":0,"strongSell":0,"meanLabel":"HOLD","meanPercent":1,"analysts":1,"updateTime":1751515200000}}}